Dexamethasome-Dexamethasomecyclophosphamide pulse therapy cyclophosphamide pulse therapy for systemic sclerosis for systemic sclerosis Sir, This is in reference to the article 'Therapeutic trials for systemic sclerosis: An update' by Sardana and Garg. [1] The comprehensive review needs the following references [2] [3] [4] [5] [6] [7] [8] to be added.
It may also be added that as many as 14 dermatologists in various institutions have used dexamethasone cyclophosphamide pulse therapy (DCP)/dexamethasone pulse therapy (DP) regimen for about 300 systemic sclerosis patients [8] and found satisfactory recoveries. DCP therapy consists of transfusing 100 mg dexamethasone dissolved in 500 ml 5% glucose over one to two hours, for three consecutive days every month, along with cyclophosphamide 500 mg on day one in the same drip and 50 mg daily, orally, in between the pulses. In DP only dexamethasone 100 mg is transfused in 500 ml 5% glucose over one to two hours for three consecutive days every month. It is used in those patients where cyclophosphamide is contraindicated.
For the information of the dermatologists, DCP / DC is able to bring about a total/almost total reversal of the changes, including skin hardening, pigmentary changes, arthritis, dysphagia, dyspnea to a variable extent, gangrene, fingertip ulceration, and even Raynand's phenomenon, which are commonly observed in progressive systemic sclerosis patients. The total treatment is to be given for three to four years. Less doses as used by those who have found unsatisfactory results, are obviously due to inadequate treatment.
Authors' reply Authors' reply
Sir, We are thankful to the author [1] [2] for evincing interest in our article. [3] 1. Firstly we focused on newer approaches in scleroderma.
Dexamethasone-cyclophosphamide pulse (DCP) therapy is by no means a new approach. 2. The evidence against use of steroids is overwhelming. There is a mountain of evidence from textbooks, and guidelines of medicine, rheumatolology and dermatology detailing the evidence against the use of steroids except for alveolitis, mycocarditis and sometimes for renal involvement [4−22] [ Table 1 ]. 3. Steroids have multitude of side effects which add to the already multisystem damage of scleroderma. [13−15] 4. Skin improvement, which is a tool observed by most Indian case reports, is the most nonspecific tool to monitor improvement. Steroids per se have no role to play in altering the skin pathology of progressive systemic sclerosis (PSS). [4] [5] [6] [7] [8] Glucocorticoids are not effective in improving or preventing skin induration and the progression of systemic sclerosis (SSc; also known as scleroderma). [14] not meet the standards of the Cochrane guidelines.
Lastly, the author has excluded two articles reporting the side-effects, which have been reported from India. [20, 21] This highlights the risks involved in the indiscriminate use of this form of therapy.
In view of the huge data from scientific journals, specialty books and international guidelines, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 21] the obstinate persistence of DCP pulse in scleroderma is purely a individual perception which is beyond scientific purview as its role has not been mentioned in any evidence-based data to date.
The summary guidelines on steroids gleaned from the wealth of data are given below [ Table 2 ]. [7] Not disease modifying -Scleroderma: In Samter's immunologic diseases [8] Not disease modifying -ACP Medicine [9] Not disease modifying
Harrison's principles of internal medicine [12] Not disease modifying Can be used for myocarditis, alveolitis
Should not be given Rheum Dis Clin North Am [13] [14] [15] [16] Not disease modifying -Should not be given
Oxford Textbook of Rheumatology [20] Not disease modifying -Should not be given 1. Low-dose prednisone (10 mg/day or less)-edematous phase (skin involvement); joint and tendon pain.
2. High-dose prednisone (20-30 mg/day) with steroid-sparing agent such as methotrexate or azathioprine-inß ammatory myositis, pericarditis, early active alveolitis.
3. Glucocorticoids have been associated with the development of renal crisis. [5, 6] 4. Diffuse cutaneous SSc showed a signiÞ cant association between prior high-dose glucocorticoids (prednisone 15 mg/d) and the development of scleroderma renal crisis double blinded trial has never shown steroids to be disease modifying [ Table 1 ]. [4−22] 6. To complicate the matter, the disease has a well known spontaneous resolution and the trial has to be factored in any reported trial that shows results. [8,15−18] In other words, a disease in the resolving phase will show a false response to any drug therapy. 7. The evidence for cyclophosphamide is there,
but as yet the results of the largest multicentric, multiregional (SCOT) trial is awaited and only after that we can comment on the therapeutic role of cyclophosphamide. [7, 12, 13, [15] [16] [17] [18] Also, all our references were of evidence-based double blinded trials, whereas the references alluded by the author [4−10] are not.
Secondly, the indexed literature does not contain references 4, 6, and 8, referred to by the author.
And case reports are not in any way considered as evidence even in the Cochrane registry of controlled trials, and most of the data reported by the author do [1] However, we would like to express our strong reservations about the usage of dinitrochlorobenzene (DNCB) despite its observed efficacy in view of the safety issues associated with it.
As established beyond doubt several years ago, DNCB is an inherently mutagenic compound. [2] Its mutagenicity was demonstrated at all concentrations in the Salmonella typhimurium plate assay. [3, 4] The assay is an invaluable screening test with a high qualitative correlation (90%) between mutagenesis and carcinogenesis. [3] In addition, DNCB depletes the activity of glutathione S transferase in rat skin, blocking an important detoxification system of mammalian cells, [5] and is found to be genotoxic by sister chromatid exchange in human skin fibroblasts. [6] Moreover, DNCB has a significant systemic absorption. [7] All the significant trials concerning DNCB have been performed before the year 1990 and there has been a steady decline in enthusiasm and publications on the use of DNCB in benign disorders of the skin after the discovery of its mutagenic potential. Therefore, in view of the possible risks involved with DNCB and the availability of newer alternative potent contact allergens, the use of DNCB to treat benign skin diseases is to be abandoned until proper carcinogenicity tests are conducted and the question of its hazard is resolved.
